NZ724285B2 - Agent for improving or preventing progression of chronic kidney disease - Google Patents
Agent for improving or preventing progression of chronic kidney disease Download PDFInfo
- Publication number
- NZ724285B2 NZ724285B2 NZ724285A NZ72428515A NZ724285B2 NZ 724285 B2 NZ724285 B2 NZ 724285B2 NZ 724285 A NZ724285 A NZ 724285A NZ 72428515 A NZ72428515 A NZ 72428515A NZ 724285 B2 NZ724285 B2 NZ 724285B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- ckd
- agent
- drug
- kidney disease
- chronic kidney
- Prior art date
Links
- 201000000522 chronic kidney disease Diseases 0.000 title claims abstract description 89
- 206010038444 Renal failure chronic Diseases 0.000 title claims abstract description 86
- 239000003814 drug Substances 0.000 claims abstract description 38
- 229940109239 Creatinine Drugs 0.000 claims description 12
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 12
- 230000001629 suppression Effects 0.000 claims description 12
- CBRIRBXLTFAPOM-UHFFFAOYSA-N 5-(hydroxymethyl)imidazolidine-2,4-dione Chemical compound OCC1NC(=O)NC1=O CBRIRBXLTFAPOM-UHFFFAOYSA-N 0.000 claims description 6
- 210000002966 Serum Anatomy 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000003247 decreasing Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 abstract description 30
- 229940079593 drugs Drugs 0.000 abstract description 28
- 230000000694 effects Effects 0.000 abstract description 27
- 239000004480 active ingredient Substances 0.000 abstract description 11
- 230000002250 progressing Effects 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 5
- 206010062237 Renal impairment Diseases 0.000 abstract 5
- UPSFNXFLBMJUQW-UHFFFAOYSA-N 5-hydroxy-1-methylimidazolidine-2,4-dione Chemical compound CN1C(O)C(=O)NC1=O UPSFNXFLBMJUQW-UHFFFAOYSA-N 0.000 abstract 2
- 230000001225 therapeutic Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 description 45
- 239000008177 pharmaceutical agent Substances 0.000 description 26
- 230000003907 kidney function Effects 0.000 description 25
- 238000000502 dialysis Methods 0.000 description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 13
- 229910052799 carbon Inorganic materials 0.000 description 13
- 239000003826 tablet Substances 0.000 description 13
- 208000009863 Chronic Kidney Failure Diseases 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 230000000274 adsorptive Effects 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 230000000750 progressive Effects 0.000 description 9
- 206010012601 Diabetes mellitus Diseases 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 7
- 239000002775 capsule Substances 0.000 description 6
- 230000037406 food intake Effects 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 210000004369 Blood Anatomy 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 229940000406 drug candidates Drugs 0.000 description 4
- 238000002651 drug therapy Methods 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000002547 new drug Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 231100000486 side effect Toxicity 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 229960005069 Calcium Drugs 0.000 description 3
- 208000008787 Cardiovascular Disease Diseases 0.000 description 3
- 229950008138 Carmellose Drugs 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 210000003205 Muscles Anatomy 0.000 description 3
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 3
- 238000009534 blood test Methods 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 230000024924 glomerular filtration Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 230000000268 renotropic Effects 0.000 description 3
- -1 sodium or potassium Chemical class 0.000 description 3
- 239000002441 uremic toxin Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 229960003624 Creatine Drugs 0.000 description 2
- 206010061428 Decreased appetite Diseases 0.000 description 2
- 210000003608 Feces Anatomy 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N Iron(III) oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 210000003734 Kidney Anatomy 0.000 description 2
- 208000001083 Kidney Disease Diseases 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 206010038435 Renal failure Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N TiO Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive Effects 0.000 description 2
- 230000001058 adult Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000006046 creatine Substances 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine zwitterion Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 229910001929 titanium oxide Inorganic materials 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Natural products NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229960000643 Adenine Drugs 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 241001553178 Arachis glabrata Species 0.000 description 1
- 206010003885 Azotaemia Diseases 0.000 description 1
- 229960004256 Calcium Citrate Drugs 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H Calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 229940105329 Carboxymethylcellulose Drugs 0.000 description 1
- 206010007554 Cardiac failure Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 230000037250 Clearance Effects 0.000 description 1
- 229960001681 Croscarmellose Sodium Drugs 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229960000913 Crospovidone Drugs 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- 208000001636 Diabetic Neuropathy Diseases 0.000 description 1
- 206010012680 Diabetic neuropathy Diseases 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headache Diseases 0.000 description 1
- 206010019280 Heart failure Diseases 0.000 description 1
- 210000000936 Intestines Anatomy 0.000 description 1
- 229940031703 LOW SUBSTITUTED HYDROXYPROPYL CELLULOSE Drugs 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000010125 Myocardial Infarction Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010029149 Nephropathy Diseases 0.000 description 1
- 206010029151 Nephropathy Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 229940093429 Polyethylene Glycol 6000 Drugs 0.000 description 1
- 229950008882 Polysorbate Drugs 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 208000005333 Pulmonary Edema Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038428 Renal disease Diseases 0.000 description 1
- 229940083542 Sodium Drugs 0.000 description 1
- 229940091252 Sodium supplements Drugs 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000009852 Uremia Diseases 0.000 description 1
- 210000002700 Urine Anatomy 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 230000003276 anti-hypertensive Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000002490 cerebral Effects 0.000 description 1
- 230000035512 clearance Effects 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 238000009588 inulin clearance Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001373 regressive Effects 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000000979 retarding Effects 0.000 description 1
- 230000000391 smoking Effects 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001959 sucrose esters of fatty acids Substances 0.000 description 1
- 235000010965 sucrose esters of fatty acids Nutrition 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 230000002522 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960005196 titanium dioxide Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Abstract
The purpose of the present invention is to provide a drug which is administered to patients suffering from chronic kidney disease that involves rapid progression of kidney dysfunction, in order to improve, or prevent the progression of, the disease state. The present invention relates to an agent for improving or preventing the progression of chronic kidney disease, the agent containing as the active ingredient 5-hydroxy-1-methyl hydantoin. This drug has exhibited a remarkable effect in patients suffering from chronic kidney disease that involves rapid progression of kidney dysfunction. This drug is extremely useful as a highly safe drug for improving, or preventing progression of, kidney dysfunction in patients suffering from rapidly progressing chronic kidney disease for which there have thus far been no effective therapeutic drugs that could be easily taken. r improving or preventing the progression of chronic kidney disease, the agent containing as the active ingredient 5-hydroxy-1-methyl hydantoin. This drug has exhibited a remarkable effect in patients suffering from chronic kidney disease that involves rapid progression of kidney dysfunction. This drug is extremely useful as a highly safe drug for improving, or preventing progression of, kidney dysfunction in patients suffering from rapidly progressing chronic kidney disease for which there have thus far been no effective therapeutic drugs that could be easily taken.
Description
AGENT FOR IMPROVING OR PREVENTING
PROGRESSION OF CHRONIC KIDNEY DISEASE
[Technical Field]
The t invention relates to a progress-suppressing or ing
agent for c kidney disease containing 5-hydroxymethylhydantoin
(IUPAC name: 5-hydroxymethylimidazolidin-2,4-dione) (hereinafter, it
will be referred to as “the present compound”) as an active ingredient.
[Background Art]
Chronic kidney disease (CKD) is a relatively new concept for a
disease proposed by the National Kidney Foundation (NKF) of the United
States in 2002. As to the cause therefor, there are various systemic diseases
and renal diseases and typical ones are diabetes mellitus, hypertension,
chronic nephritis, etc. CKD is defined as such ones where any of the
following (1) and (2) or both continue(s) for three months or more. They are:
(1) The case where the existence of nephropathy is clear as a result of
urine test, image and pathological diagnosis, blood test, etc. and particularly
where not less than 0.15 g/gCr of proteinuria (not less than 30 g/gCr of
albuminuria) is detected. (The unit “/gCr” means “per gram of creatinine”.)
(2) The case where glomerular filtration rate (GFR) lowers to an
extent of less than 60 mL/minute/1.73 m2. (GFR will be ned later.)
As a result of an increase in the occurrence frequency of life
style-related es such as diabetes mellitus and ension in recent
years, CKD is also increasing steadily. For example, it has been ned
that the numbers of patients with CKD in Japan are 13,300,000 and reaches
about 13% (one patient in about eight persons) of the adult population
(“Guide for Diagnosis of CKD - 2012” edited by the Japanese Society of
Nephrology).
The first problem when one suffers from CKD is that the renal
function lowers whereby waste products and water are unable to be excreted.
As a result, dropsy is ted or one feels languid. In on, vomiting,
headache and anorexia are resulted due to uremia. Further progress
thereof s complications such as cardiovascular diseases (CVD) such as
myocardial infarction, cardiac failure and cerebral apoplexy and pulmonary
edema whereby crisis of life becomes high.
When end-stage kidney disease (ESKD) is resulted as the progress of
the CKD, dialysis and kidney transplantation are necessary. For example,
in Japan, patients who need the dialysis are ly increasing and, in 2011,
they were more than 300,000. That is one of the causes of swelling the
national medical expenses and is a big problem in view of medical economy
as well. Moreover, because dialysis treatment is to be done usually three
times a week and requires four to five hours for each dialysis, that is a big
burden in the daily life of a patient and greatly deteriorates the QOL.
Accordingly, it is important to try not to result in a state where the dialysis
treatment is necessary due to the occurrence of ESKD and also to try to
retard the stage of initiating the is treatment as long as possible.
(The CKD before the start of the dialysis ent as such is called “CKD in
a conservative stage”.) In view of the above, there has been a brisk demand
for pharmaceutical agents having a suppressive effect for the progress of
CKD and exhibiting a high safety.
Human renal function is sed by a glomerulus rate (CFR) which
is the amount of plasma per unit time by all glomerular bodies in the .
A decrease in GFR means a decrease in the renal function. As a result
thereof, metabolites in the body such as creatinine (Cr) and blood urea
nitrogen (BUN) are unable to be excreted into urine but are accumulated in
the body. As a reflection thereby, data of creatinine and BUN become high
in the blood test. For precisely measuring the GFR, a esome test
called inulin clearance or creatinine clearance is necessary. However, in the
daily diagnosis where such a test is difficult, there has been used a simplified
method in which serum creatine (sCr) value is measured by a blood test and,
based on said value er with age and sex, an estimated glomerular
filtration rate (eGFR) is calculated. For example, a calculation formula for
eGFR suitable for the se is proposed in “Evidence-based ce
Guidelines for the treatment of CKD - 2013” edited by the Japanese Society
of Nephrology), etc. In addition, the stage of CKD is roughly classified into
five (the first stage to the fifth stage). Since the GFR value in the third
stage (stage 3) or higher is less than 60 mL/minute/1.73 m2 (as hereinafter,
the unit for the GFR value will be omitted), that is the CKD (refer to the
above definition for CKD in (2)). When the GFR is less than 15, that is the
fifth stage (stage 5) and is ESKD.
The GFR value in a healthy person is 60 or more. In a patient with
CKD of stage 3 and more where the GFR value is less than 60, metabolites
such as creatinine begin to be accumulated in blood whereby serum
creatinine value and blood urea nitrogen value begin to rise significantly.
In a slowly progressive patient where the GFR value worsens to an extent of
only less than 10 in one year, the time until becoming ESKD whereby
dialysis is to be introduced is still left to some extent. In such a patient,
there is conducted a measure where ss of the disease is made to retard
by a therapy where blood pressure and blood sugar are normalized, a
smoking ion y and a diet therapy where ion of salt and
protein is restricted so as to prevent to become ESKD (Therapies as such are
called “conservative therapy” of CKD.). Since hypertension is the biggest
risk factor for the occurrence and the progress of CKD and also for the
occurrence of CVD, control of blood pressure is particularly important. As
to an antihypertensive, angiotensin-converting enzyme (ACE) inhibitor and
ensin II receptor r (ARB) have been mainly used in ation,
depending upon a patient, with diuretic agent, calcium antagonist, etc.
The time-dependant changes of the renal function in CKD can be
aware of by means of chronological plotting of the GFR values. Thus, when
a graph is drawn where an ordinate is for the eGFR value while an abscissa
is for the time ), a worsening speed of the renal function can be noted.
It is general in CKD that the GFR value linearly lowers from upper left to
lower right. When the slope of this line is made as small as le by
means of a diet therapy or a drug therapy, the stage where ESKD is resulted
and a dialytic treatment is necessary can be retarded.
The ependant changes in the renal function in CKD is also
able to be aware of by plotting the reciprocal serum creatine (sCr) values
(1/sCr; hereinafter, it will be sometimes called rocal sCr value”). That
is because the reciprocal sCr value is proportional to the GFR value. When
the renal function is evaluated by the sCr value, ranges of normal standard
values are usually within a ranges of 0.5 to 1.1 mg/dL and 0.4 to 0.8 mg/dL
(hereinafter, the unit will be omitted) for males and females, respectively.
Since creatinine is ed in muscles, its amount is proportional to the
muscle amount and, generally, that in males is higher than that in females to
an extent of 10 to 20%. In addition, it rarely varies depending upon the age.
In elderly persons, the renal glomerular filtration rate lowers with the age
but, since the muscle amount also decreases therewith, the sCr value
becomes nearly constant. In case the renal function is evaluated by means
of the sCr value, a follow-up observation will be necessary in some cases
when the values in male and female reach 1.2~1.3 and 0.9~1.0, respectively.
Generally, in moderate CKD, the sCr value exceeds 1.5 and, in a critical
condition, it is 2.4 or even more. When the sCr value exceeds 5, recovery is
difficult and the stage where the sCr value is 10 is a yardstick for starting
the dialysis. Generally, in the actual site of medical care, it is common that
an appropriate treatment is investigated by observing the elapse of GFR
values, reciprocal sCr values or sCr values for several months to know the
worsening velocity of CKD of a patient.
In patients with CKD, there are those in such a type where slope of a
straight line plotted by GFR values or that plotted by reciprocal sCr values
(hereinafter, the latter will be called “slope of reciprocal sCr values”) is
relatively gentle and those in such a type where the slope is steep. For the
former patients, it is possible to some extent to retard the ss to ESKD
(to extend the period of CKD in a conservative stage) by a diet y or a
drug therapy. However, for the patients where the GFR value or the
reciprocal sCr value rapidly lowers and worsening of the symptom proceeds,
there has been almost no therapeutic agent which effectively suppresses it.
Once the patient reaches ESKD, dialysis is ary in addition to a diet
therapy and a drug therapy and QOL of the patient is very much
deteriorated as mentioned already.
Under such circumstances, a spherical adsorptive carbon as a
pharmaceutical agent has been approved in Japan where the indication is
vement in uremic symptom in progressive chronic renal failure and
ation of introduction of dialysis”. In short, this agent is ted
carbon. When this agent is ingested (each 2 g, three times daily, 6 g in total),
uremic toxin in a patient with CKD is adsorbed with an intestine and
excreted together with feces whereby there is ed an effect of improving
the uremic symptom and of retarding the introduction of dialysis. For
example, according to the package insert for “Kremezin (Registered Trade
Mark)” which is the original spherical adsorptive carbon preparation in
Japan, the slope of ocal sCr values was significantly improved to -222
378 10-5 dL/mg.week (hereinafter, the unit will be omitted) from -329 245
before the administration in a clinical test (double-blind test) where said
preparation was administered in a daily dose of 6 g per day (three times 2
grams) for 24 weeks to “patients with progressive chronic renal failure”. (In a
o group, the data before and after the administration were -293 184
and -274 279, respectively.) In view of the above, there is no doubt that
“Kremezin (Registered Trade Mark)” is an epoch-making drug which brought
the big gospel to the patients with CKD. ing to “Interview Form of
Pharmaceutical Agent” for said agent, it has been sold in Asian countries
such as Korea, Taiwan and the Philippines since its approval in Japan in
1991 gh it has not been sold in Europe and America.
Incidentally, even a spherical adsorptive carbon preparation which is
an epoch-making pharmaceutical agent, there are still some problems.
y, the spherical tive carbon preparation has a problem that a
dose of 6 g per day which is very high amount as a pharmaceutical agent
should be ingested. Dosage forms of the spherical adsorptive carbon
preparations sold in Japan are capsule and fine granules (powdered drug).
With regard to the capsule, since one capsule contains 200 mg of the
ient, one must ingest ten capsules at a time. Therefore, its daily dose
is 30 capsules. Since that made the compliance of patients bad, r
dosage form additionally approved in 2000 is fine granules (powdered drug).
In the fine granules, since one pack contains 2 g, one pack at a time is
ingested with water. When the fine granules are not well swallowed, the
inner area of the mouth sometimes becomes entirely black. Therefore, it is
ended to swallow with some modifications such as to swallow after
ng with a bag-shaped wafer (after dividing into several wafers if
ary) or to suck through a straw after being sunk in water in a cup.
This should be conducted three times a day. In addition, it sometimes
happens that, when the spherical adsorptive carbon ation is ingested,
the feces become black. In view of the above, there is a problem that the
compliance upon ingestion of the spherical adsorptive carbon preparation is
still bad. Moreover, the spherical adsorptive carbon preparation sometimes
causes a side effect such as constipation or anorexia. When constipation
happens, the effect of this drug decreases as well. In addition, since the
spherical adsorptive carbon ation adsorbs a chemical substance, when,
for example, another pharmaceutical agent for hypertension or diabetes
mellitus is administered together, there is a big problem that the active
ingredient of the pharmaceutical agent is also ed resulting in a
decrease in the effect. Therefore, in a package insert for the cal
adsorptive carbon preparation, there is a description reading “When another
agent is used together, it is to be taken into consideration that this agent is
an adsorbent and the ingestion of another agent together with this agent
should be avoided” as the “important ental notice” whereby ingestion
together with another agent at the same time is prohibited. Under the
current circumstances as such, there has been a brisk demand for the
development of pharmaceutical agents for a patient with CKD where the
effect is excellent, the side effect is little, the ingestion is easy and the
simultaneous ingestion with another agent is possible.
The present nd (5-Hydroxymethylhydantoin) was created
by Nippon Zoki Pharmaceutical Co., Ltd. who is the applicant for the present
application (Japan Patent pen No. sho114578 and Japanese
Patent No. 1,616,338). After that, the present compound was found to be
effective for renal failure due to the suppression of production of uremic toxin
(Patent Document 1). In Patent Document 1, there is described that the
present compound has an action of lowering the uremic toxin such as urea
nitrogen and creatinine in animal experiments using the rats with c
renal failure induced by oral administration of adenine. However, there is
no description therein at all for the optimum dose of the present compound to
humans and also for the fact that, in case what type of a CKD-suffering
patient is administered with the present compound, the effect for
suppressing the progress of CKD can be icantly achieved.
In the meanwhile, the results of clinical tests of the present
compound were presented at the meetings in 1997 and 1999 (Non-Patent
Documents 1 and 2). In those documents, it is shown that the present
compound sses the ng of the reciprocal sCr value (1/sCr) of a
patient with diabetic chronic renal failure (hereinafter, it will be ed to
as tic CRF”). However, pharmaceutical effects of the present
compound are not compared after dividing the symptoms of patients into
progressive and non-progressive ones. In on, the effect of the present
compound shown by those clinical test results cannot be said to be so
significant and no development of the t compound has been conducted
thereafter. Incidentally, the Non-Patent Documents 1 and 2 will be
mentioned later in detail under the columns of Referential Example.
[Prior Art Documents]
[Patent Documents]
Patent Document 1: Japanese Patent Laid-Open No. Hei72463
[Non-Patent Documents]
Non-Patent Document 1: XVth International Congress of Nephrology,
Buenos Aires, 385, 1997
Non-Patent Document 2: J. Am. Soc. Neph., 10, 131A, 1999
[Summary of the Invention]
[Problem to be Solved by the Invention]
The problem of the present invention is to provide a very highly
useful progress-suppressing or improving agent for CKD, where worsening of
renal function of patients with rapidly progressive CKD for which no
effective and easily ingestible therapeutic agent has been ble up to now
is able to be suppressed or improved. atively or additionally, an object
of the present invention is to at least e the public with a useful choice.
[Means for Solving the Problems]
The present inventors have conducted the studies in more detail for
the effect to CKD by means of clinical tests in CKD patients using a
pharmaceutical agent ning the present compound as an active
ingredient (hereinafter, the agent will be referred to as “the present agent”).
As a result, it has been found that, when the present compound is ingested in
a relatively high dose, a selective and icant effect is achieved for
patients where lowering of renal function is rapidly progressing among the
patients with CKD whereupon the t invention has been accomplished.
In the present compound, toxicity is very low and almost no side effect is
noted. Therefore, there was no problem in terms of safety for the patients
with CKD to whom a relatively high dose was stered. In on,
the present agent can be administered orally and its simultaneous
administration with another pharmaceutical agent is not denied as well.
Therefore, the t agent is quite useful as a ss-suppressing and
improving agent for CKD.
[0015a]
Accordingly, in one aspect, the present invention relates to use of
-hydroxymethylimidazolidin-2,4-dione in the manufacture of a
medicament for oral administration in a dose of 800 200 mg of
-hydroxymethylimidazolidin-2,4-dione per day for suppressing the
progress of or improving chronic kidney disease in a patient with chronic
kidney disease where the patient’s reciprocal serum creatinine value per
month is decreasing by 0.01 dL/mg or more.
[0015b]
In the description in this ication reference may be made to
subject matter which is not within the scope of the appended claims. That
subject matter should be readily identifiable by a person skilled in the art
and may assist in putting into practice the invention as defined in the
appended claims.
tages of the Invention]
The present agent showed a icant effect in a selective manner to
such a patient where lowering of renal function is rapidly progressing among
the patients with CKD. Although dose of the present agent is relatively
high, no side effect causing the inconvenience is found. Accordingly, the
present agent is very highly useful as a pharmaceutical agent where
worsening of renal on of patients with rapidly progressive CKD for
whom no effective and easily ingestible therapeutic agent has been available
can be suppressed or improved and, at the same time, safety is very high,
ingestion is easy and simultaneous use with another pharmaceutical agent is
not denied.
[Brief Description of Drawings]
[Fig. 1] Fig. 1 shows the result where the t compound was
orally administered in a dose of 200 mg or 400 mg per day to patients with
diabetic CRF and the changes in the renal function before and after the
administration of the test drug were compared by means of inclination of
regression lines to the reciprocal sCr values.
[Fig. 2] Fig. 2 shows the result where the placebo or the present
compound was orally administered in a dose of 800 mg or 1600 mg per day to
patients with CKD having different ssive property and the changes in
the renal function before and after the administration were compared by
means of inclination of regression lines to the reciprocal sCr values.
[Fig. 3] Fig. 3 is a graph g the changes in the reciprocal
inclination of sCr values when the placebo or the present compound was
orally administered in a dose of 800 mg per day to patents with CKD where
ing of the renal function is rapidly progressing.
[Fig. 4] Fig. 4 is a graph showing the changes in the reciprocal
inclinations of sCr values for all cases covering five test subjects of a
placebo-administered group and five test subjects of a 800 mg/day of test
drug-administered group.
[Mode for Carrying Out the Invention]
The present invention relates to an agent for ssing the
progress of or for improving the chronic kidney disease (CKD) containing
-hydroxymethylhydantoin (the present compound) as an active
ingredient
With regard to 5-hydroxymethylhydantoin (the present compound)
which is an active ingredient in the present invention, there may be
exemplified a salt with alkali metal such as sodium or potassium, with alkali
earth metal such as calcium or magnesium or with metal such as aluminum
or a salt with a base such as ammonia or organic amine. The salt as such
may be produced from a free compound by a well known method or may be
converted each other.
The present compound includes optical isomers thereof and, when it
exists in a form of hydrate, solvate or complex compound, the present
invention covers any of them. With regard to crystal polymorphism of the
present nd, it has been known that crystals of type I and type II exist
and the present compound includes various crystal forms (crystal
polymorphism) being able to be formed including the above crystal forms.
Production process and crystal polymorphism of the present compound are
disclosed in Japanese Patent pen No. Sho114,578, International
ation WO ,934, etc.
The present compound may be made into a pharmaceutical
preparation wherein s pharmaceutical additives suitable for the
dosage form such as excipient, , wetting agent, egrating agent,
lubricant and diluent are combined as necessary. Among them, the dosage
form which is most simple and convenient for a patient is an oral preparation.
As to the oral ation, it is possible to make into a dosage form such as
tablets, capsules, diluted powder, granules, liquid and syrup.
With regard to the additive for making into an oral preparation,
there may be exemplified excipient, , disintegrating agent and
lubricant. es of the ent include saccharide such as lactose,
sugar alcohol such as mannitol, crystalline cellulose, corn starch and potato
starch. Examples of the binder include hydroxypropylmethylcellulose,
hydroxypropylcellulose, alpha-starch, polyvinylpyrrolidone, pullulan,
crystalline cellulose, cellulose derivatives, gum arabic, corn starch and
gelatin. Examples of the disintegrating agent include carmellose,
carmellose calcium, carboxymethyl starch sodium, low substituted
hydroxypropylcellulose, crospovidone, croscarmellose sodium, corn starch,
potato starch and carboxymethylcellulose potassium. Examples of the
lubricant include talc, magnesium stearate, sucrose esters of fatty acids,
hydrogenated oil and stearic acid. In addition to the above, extender,
wetting agent, buffer, preservative, flavoring, etc. may be riately
ed therewith and corrigent, aromatizing agent, etc. may also be added
thereto. In the case of tablets, it is also possible to make into a film-coated
tablet, etc. where a coat is applied to a plain tablet using an appropriate
coating agent such as a polymer compound. As to the coating agent, there
may be used a ly used one such as hydroxypropylmethylcellulose,
hydroxypropylcellulose, methylcellulose or polyvinylpyrrolidone. As to a
g aid, there may be used polyethylene glycol 6000, polysorbate,
titanium oxide or dye such as red iron oxide, etc.
An example of the formulations for the manufacture of the present
pharmaceutical agent in a form of tablets where each tablet contains 400 mg
of the t compound is shown below, although the present invention
shall not be d thereto at all.
[Plain ] (mg/tablet)
Present compound 400.0
Calcium citrate 80.0
Crystalline cellulose 94.0
Hydroxypropylcellulose 8.0
Carmellose calcium 6.0
Talc 6.0
Magnesium stearate 6.0
(Subtotal) 600.0
[Coat] (mg/tablet)
Hydroxypropylcellulose 11.0
ol 6000 2.2
Crystalline cellulose 3.2
Titanium oxide 1.6
(Subtotal) 18.0
(Grand total) 618.0
The preferred dose of the present compound may vary ing
upon the object to be administered (age, body , etc. of a patient), type
and degree of the disease, dosage form, administering method, administering
period, etc. However, according to the result of the clinical test mentioned
in the following Examples, 800 200 mg, preferably 800 100 mg or, more
preferably, 800 mg of the present compound may be usually administered to
an adult as a dose for one day in order to achieve the desired effect by oral
administration to . The above daily dose may be administered
either at a time or by dividing into two or three times.
[Examples]
Now the result of the clinical test using the present agent (where the
dosage form is a tablet) will be shown as hereunder. Firstly, the result of
the clinical test conducted in the past is shown as a Referential e.
Then, the result of the al test conducted recently is shown as an
e whereby the significance of the present invention is specifically
illustrated, although the present invention shall not be limited at all by
them.
Referential Example - Result of the clinical tests (1)
The clinical tests shown in Non-Patent Documents 1 and 2 will be
explained as follows. Non-Patent Document 2 is a follow-up report of the
clinical test of tent Document 1. As hereinafter, the clinical tests
concerning those documents will be referred to as the “old clinical tests”.
In the old clinical tests, a test drug was orally administered once
daily for 24 weeks where an object was a patient with diabetic CRF and then
the efficacy and the safety of the present compound were evaluated.
Persons who were the patients receiving a conservative therapy for diabetic
CRF and meet the following selection criteria were selected as test ts.
1) The sCr value is 1.5 mg/dL or more and continues to increase
tently.
2) Creatinine nce is less than 50 mL/minute.
3) A person is suffer from diabetic neuropathy.
Results of the old clinical tests were compared by means of the
changes in the ocal inclination of sCr values in a test subject before and
after the administration of the test drug.
There is the following disclosure in Non-Patent Document 2 for the
e and the result of the old clinical tests. (“Pharmaceutical agent” in
Patent Document 2 means a tablet containing the present compound.
ntally, there are some es therein where this pharmaceutical
agent or the present nd is sed in a development number
reading 9”.)
“Twenty-six cases were registered (55.8 years old in average) and
divided into two groups comprising a 200 mg administered group (13 cases)
and a 400 mg administered group (13 cases). In four cases, complicating
symptoms became worse and were dropped. Clinical effect was evaluated
by means of the reciprocal sCr value (1/sCr). During the period of more
than three months before the administration of the pharmaceutical agent,
the sCr values were measured for at least five times and adopted as a control
value of a test subject. The sCr value immediately before the first
administration of the pharmaceutical agent was within a range of 1.7 to 4.0
mg/dL. After administering the pharmaceutical agent, the sCr values were
measured in the second, fourth, eighth, twelfth, sixteenth, twentieth and
twenty-fourth weeks. The 1/sCr values versus time were plotted and a
sion line was prepared by means of the square method.
Changes in the inclination of the regression line were compared at the stages
of before and after administering the pharmaceutical agent. The following
differences were noted statistically significantly and they show that
steepness of the inclination was ed by the pharmaceutical agent.
200 mg/day administered group (n = 11): -0.00075 0.00066 before
the administration and -0.00046 0.00043 after the administration (p =
0.01)
400 mg/day administered group (n = 11): -0.00098 0.00077 before
the administration and -0.00066 0.00097 after the administration (p =
0.02)
(Mean value S. D.)
No critical side effect by the pharmaceutical agent was noted in the
clinical test and in the clinical symptom. During the course of the clinical
test, no accumulation of the pharmaceutical agent was ”
The above result made into a graph is Fig. 1.
In Non-Patent Document 1, the part of the final result is as
mentioned below and that is the difference from Non-Patent Document 2.
“200 mg/day administered group (n = 12: -0.00078 0.00064 before
the administration and -0.00040 0.00047 after the stration (p =
0.016)
400 mg/day administered group (n = 11): -0.00098 0.00077 before
the administration and -0.00068 0.00096 after the stration (p =
0.024)”
Example - Result of the clinical test (2)
Results of the old clinical tests show a certain effect of the present
compound to the diabetic CRF. However, as will be understood from Fig. 1,
it was evaluated that the effect was not so surprisingly significant.
Therefore, pment of the present compound as a therapeutic agent for
ic CRF or CKD had been ceased.
During such a period, a good idea has occurred that the effect of the
present compound is investigated after dividing the patients with CKD into
groups where worsening of the renal function is rapid and is not. As a
result, the patients with CKD were divided into a group where changes in
the reciprocal sCr value (1/sCr) per month before administration of the test
drug are 0.01 dL/mg or more and worsening of the renal function is rapidly
progressing (hereinafter, that will be referred to as “rapidly progressive CKD
ts”) and another group where said changes are less than 0.01 dL/mg
(hereinafter, that will be ed to as “slowly progressive CKD patients”)
and clinical tests comparing the effect of the present compound were
carried out. (Hereinafter, that will be referred to as “new clinical tests”.)
Such a yardstick where the changes in the reciprocal sCr value are 0.01
dL/mg or more followed the yardstick d in the application of
zin (Registered Trade Mark)” which is the above-mentioned spherical
adsorptive carbon preparation. Further, in the new clinical tests, dose of
the t compound was increased to some extent so as to find the
ence from the results in the old clinical tests. Summary and result of
the new clinical tests will be mentioned as follows.
A clinical test for evaluating the efficacy and the safety of the present
compound was conducted using the patients where the CKD stage was 3 or 4
as the object. Persons who meet the following selection criteria were
selected from the patients who were sed as CKD and receiving a
conservation therapy.
Sexis withdrawn from the consideration. Pregnant women and
mothers suckling a baby are however excluded.
Age is from 20 to 75 years old.
GFR value is 15 to 59.
ts where the serum creatinine (sCr) value is within a range of
1.5 to 5.0 mg/dL at the start of the test, the measuring frequencies from 52
weeks before the test until the start of the test are thrice or more and the
difference in the tested values in the initial and the final stages is 0.2 mg/dL
or more (showing a rise).
Patientswhere a therapy with a pharmaceutical agent which is
thought to suppress the progress of CKD (such as a cal adsorptive
carbon preparation) or a diet therapy is newly started during three month
before the start of the test are excluded.
Moreover, patients having a symptom of cerebrovascular
disturbance, patients with infectious disease and patients with peptic ulcer
are excluded.
After that, the objects were divided into the rapidly-progressive CKD
patients and slowly-progressive CKD patients.
As a result, in the new al tests, the groups to which the tablets
containing the present compound as an active ingredient (test drug) are
administered and to which the s containing no active ingredient
though being inguishable from the test drug are divided into six
groups in total. Thus, they are three groups for slowly-progressive CKD
patients comprising a placebo-administered group, a 800 mg test
drug-administered group and a 1600 mg test drug-administered group and
other three groups for a rapidly-progressive CKD patients comprising a
placebo-administered , a 800 mg test drug-administered group and a 1600
mg test drug-administered group whereby there are six groups in total. The
weight mentioned hereinabove is a weight of the present compound
contained in the test drug and is a dose for one day. ntally, in the new
al tests, administration was done once daily. A test drug containing
400 mg of the present compound per tablet was used. Therefore,
administration of a 800-mg test drug means that two tablets of the test drug
are administered and administration of a 1600-mg test drug means that four
tablets of the test drug are administered. In a placebo, lactose is used as a
substitute for the present compound which is an active ingredient and
adjustment with the amount of another additive was done so that the total
weight is made the same as that of the test drug. Both of the test drug
and the placebo are called “investigational drug”.
The igational drug was orally administered to test subjects
once daily during 24 weeks. The administering time was made 30 minutes
before breakfast if at all possible. ations of the regression line to the
reciprocal sCr values (1/sCr) before and after administration of the
investigational drug were compared to evaluate the effect of the
investigational drug for the progress of CKD. Test of significance was done
by means of Dunnett test.
To be more specific, changes in the renal function between the stage
of 24 weeks before the stration of the investigational drug and the
stage of 24 weeks after the start of the administration were evaluated by
means of the inclination of a regressive line to the ocal sCr values
(1/sCr). As a result, progress of ing of the renal function in a
rapidly-progressive CKD patient was significantly suppressed or improved
by administration of 800 mg/day of the present compound as shown in Fig. 2.
This result was found to be statistically significant as well. No such an
effect was achieved in a slowly-progressive CKD patient showing the
selectiveness to a y-progressive CKD patient. In a 1600
mg/day-administered group, a certain effect was noted in a
rapidly-progressive CKD patient but the effect was not so significant. No
effect was noted in a slowly-progressive CKD patient. In a group where a
placebo was administered to a y-progressive CKD patient, no change
in the renal on was noted at all.
The outcome where the above result is shown in terms of changes in
the reciprocal inclination of sCr values is Fig. 3. In the rapidly-progressive
CKD patient group, the downward-sloping inclination does not change at all
between before and after the treatment in a placebo-administered group
(average of five test subjects) while, in th e 800 mg present compound
-administered group (average of five test subjects), a downward-sloping
inclination becomes somewhat upward rather than te whereby the
progress of the renal function decrease is suppressed or ed (solid line
in the graph of the right hand side in Fig. 3). Although the case numbers
are limited, this result exceeds the effect of the above “Kremezin (Registered
Trade Mark)”. For reference, changes in all of the reciprocal inclinations of
sCr values for five test subjects in a placebo-administered group and for five
test subjects in a 800 mg/day test drug-administered group among the
rapidly-progressive CKD patients are shown in Fig. 4. It is noted from Fig.
4 that worsening of the renal function in all of the five test subjects in a 800
mg/day test drug-administered group is significantly ssed or improved.
On the other hand, it is noted that worsening of the renal function in the five
test subjects in a placebo-administered group is not suppressed at all (no
change is noted) (solid line in the graph of the left hand side in Fig. 3).
Incidentally, in all of the cases including the 1600 -administered
group, no critical side effect becoming a problem is observed whereby it has
been recognized that the present pharmaceutical agent is of very high safety.
As mentioned already, for rapidly-progressive CKD patients, there is
no therapeutic agent which is effective for suppressing the progress of the
renal function decrease and is simply and conveniently ingestible. Under
such circumstances, the effect of the present compound is prominent and the
renal function can be kept almost in a state of upon the start of the therapy
whereby the period for introducing the dialysis can be greatly extended and,
in some cases, nce thereof can be expected. As a result, it is a matter
of course that prevention of ng of QOL of a patient is achieved and
there is also a possibility of ing the survival period. lly, drug
therapy achieves its effect when administration is done before the symptom
becomes al and there are many cases where the outcome is not so
effective when the symptom becomes critical. However, as shown in Figs. 2
to 4, the present compound has such a specific effect that it is not achieved in
a slowly-progressive CKD patient where the symptom is not yet critical but
is achieved in a rapidly-progressive CKD patient where the early
introduction of dialysis is felt . Incidentally, if the period for
introducing the dialysis of the rapidly-progressive CKD patient can be
ed, there is also a possibility that it is effective for suppressing the
se in the national medical expenses.
[Industrial Applicability]
-Hydroxymethylhydantoin which is the active ingredient of the
present pharmaceutical agent showed a significant effect to a patient where
ing of the renal function rapidly proceeds among the patients with
CKD. The present pharmaceutical agent can suppress or e the
worsening of the renal function in the above patient where no effective
therapeutic agent being able to be easily administered has been available
and the agent also shows high safety and is easily ingestible whereby it has a
quite high usefulness.
In this specification where reference has been made to patent
specifications, other external documents, or other sources of information,
this is generally for the purpose of providing a context for discussing the
features of the invention. Unless specifically stated otherwise, reference to
such external documents is not to be construed as an ion that such
documents, or such sources of information, in any jurisdiction, are prior art,
or form part of the common general knowledge in the art.
Claims (7)
- [Claim 1] Use of 5-hydroxymethylimidazolidin-2,4-dione in the manufacture of a medicament for oral administration in a dose of 800 200 mg of 5-hydroxymethylimidazolidin-2,4-dione per day for suppressing the ss of or improving chronic kidney disease in a patient with chronic kidney disease where the patient’s reciprocal serum creatinine value per month is decreasing by 0.01 dL/mg or more.
- [Claim 2] The use according to claim 1, wherein the dose is 800 100 mg per day.
- [Claim 3] The use according to claim 1, wherein the dose is 800 mg per day.
- [Claim 4] The use according to any one of claims 1 to 3, wherein the patient with chronic kidney disease is in a stage 3 or 4 of the chronic kidney disease.
- [Claim 5] The use according to claim 4, n the medicament is for oral administration once daily.
- [Claim 6] The use according to any one of claims 1 to 5, wherein the medicament is in a form of a tablet.
- [Claim 7] The use according to any one of claims 1 to 6 substantially as herein described with reference to any example thereof and with or t reference to the accompanying drawings.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014034792 | 2014-02-26 | ||
JP2014-034792 | 2014-02-26 | ||
PCT/JP2015/055397 WO2015129750A1 (en) | 2014-02-26 | 2015-02-25 | Agent for improving or preventing progression of chronic kidney disease |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ724285A NZ724285A (en) | 2021-01-29 |
NZ724285B2 true NZ724285B2 (en) | 2021-04-30 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021502403A (en) | Ganaxolone used to treat hereditary epileptic disorders | |
AU2015223908B2 (en) | Progress-Suppressing or Improving Agent for Chronic Kidney Disease | |
CN112789041A (en) | Composition for reducing serum uric acid | |
JP6499634B2 (en) | Combination of solifenacin and salivary stimulant for the treatment of overactive bladder | |
US20120289564A1 (en) | Combinations of oxybutynin and salivary stimulants for the treatment of overactive bladder | |
Cass et al. | Effect of renal impairment on the pharmacokinetics of intravenous zanamivir | |
US20160175311A1 (en) | Use of pemirolast in the treatment of acute asthma | |
US20220347181A1 (en) | Agent for treating nocturnal pollakiuria | |
NZ724285B2 (en) | Agent for improving or preventing progression of chronic kidney disease | |
KR102512518B1 (en) | Medicines containing pemafibrate | |
KR20230129628A (en) | Methods of administering anti-fibrotic therapy | |
JP2014513689A (en) | Combination of trospium and salivary stimulants for the treatment of overactive bladder | |
Brashier et al. | Tenapanor: new approach to counter irritable bowel syndrome with constipation | |
TW202430175A (en) | Therapeutic tyrosine kinase inhibitors for multiple sclerosis |